4//SEC Filing
GKCC, LLC 4
Accession 0000950170-25-035494
CIK 0001601485other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:06 PM ET
Size
8.9 KB
Accession
0000950170-25-035494
Insider Transaction Report
Form 4
GKCC, LLC
10% Owner
Transactions
- Conversion
Convertible Note (convertible into Common Stock)
2025-03-05$5.81/sh−3,442,341$20,000,001→ 0 total(indirect: By LLC)Exercise: $5.81→ Common Stock (3,442,341 underlying) - Conversion
Common Stock
2025-03-05$5.81/sh+3,500,573$20,338,329→ 5,416,212 total(indirect: By LLC)
Chudnovsky Yekaterina
Director10% Owner
Transactions
- Conversion
Convertible Note (convertible into Common Stock)
2025-03-05$5.81/sh−3,442,341$20,000,001→ 0 total(indirect: By LLC)Exercise: $5.81→ Common Stock (3,442,341 underlying) - Conversion
Common Stock
2025-03-05$5.81/sh+3,500,573$20,338,329→ 5,416,212 total(indirect: By LLC)
Footnotes (2)
- [F1]Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.
- [F2]The Convertible Note had a stated maturity date of February 15, 2026. The Convertible Note, including any accrued but unpaid interest, was converted into shares of Common Stock on March 5, 2025 at a conversion price of $5.81 per share.
Documents
Issuer
Elicio Therapeutics, Inc.
CIK 0001601485
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001977769
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 4:06 PM ET
- Size
- 8.9 KB